- $160.70m
- $91.00m
- $3.93m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.17 | ||
| Price to Tang. Book | 10.77 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 40.94 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -109.12% | ||
| Return on Equity | -160.8% | ||
| Operating Margin | -3440.23% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 103.18 | 14.27 | 26.91 | 6.22 | 3.92 | 11.13 | 132.73 | -46.64% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Directors
- Randal Kirk CHM (67)
- Helen Sabzevari PRE (59)
- Harry Thomasian CFO (59)
- Jeffrey Perez SVP (49)
- Donald Lehr EXO (46)
- Robert Shapiro LED (82)
- Cesar Alvarez IND (73)
- Steven Frank IND (61)
- Vinita Gupta IND (53)
- Fred Hassan IND (75)
- Jeffrey Kindler IND (64)
- Dean Mitchell IND (65)
- James Turley IND (66)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 19th, 2004
- Public Since
- August 8th, 2013
- No. of Shareholders
- 286
- No. of Employees
- 143
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 107,130,903
- Address
- 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, 20876
- Web
- https://precigen.com/
- Phone
- +1 3015569900
- Auditors
- Deloitte & Touche LLP
Upcoming Events for PGEN
Precigen Inc Annual Shareholders Meeting
Q2 2025 Precigen Inc Earnings Release
Similar to PGEN
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Precigen share price?
As of Today at 22:44 UTC, shares in Precigen are trading at $1.50. This share price information is delayed by 15 minutes.
How has the Precigen share price performed this year?
Shares in Precigen last closed at $1.50 and the price had moved by +7.14% over the past 365 days. In terms of relative price strength the Precigen share price has underperformed the S&P500 Index by -1.1% over the past year.
What are the analyst and broker recommendations for Precigen?
The overall consensus recommendation for Precigen is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Precigen dividend yield?
Precigen does not currently pay a dividend.
Does Precigen pay a dividend?
Precigen does not currently pay a dividend.
When does Precigen next pay dividends?
Precigen does not currently pay a dividend.
How do I buy Precigen shares?
To buy shares in Precigen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Precigen?
As of the previous close price of $1.50, shares in Precigen had a market capitalisation of $160.70m.
Where are Precigen shares listed?
Here are the trading details for Precigen:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PGEN
What kind of share is Precigen?
Based on an overall assessment of its quality, value and momentum Precigen is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Precigen share price forecast for 2025?
The analyst consensus target price for shares in Precigen is $6.00. That is 300% above the last closing price of $1.50.
Analysts covering Precigen currently have a consensus Earnings Per Share (EPS) forecast of -$0.27 for the next financial year.
Find out moreWhat is the trend in the Precigen share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Precigen. Over the past six months, its share price has outperformed the S&P500 Index by +86%.
As of the last closing price of $1.50, shares in Precigen were trading +21.95% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Precigen PE Ratio?
The Precigen PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Precigen?
Precigen's management team is headed by:
- Randal Kirk - CHM
- Helen Sabzevari - PRE
- Harry Thomasian - CFO
- Jeffrey Perez - SVP
- Donald Lehr - EXO
- Robert Shapiro - LED
- Cesar Alvarez - IND
- Steven Frank - IND
- Vinita Gupta - IND
- Fred Hassan - IND
- Jeffrey Kindler - IND
- Dean Mitchell - IND
- James Turley - IND